• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CRBP

    Corbus Pharmaceuticals Holdings Inc.

    Subscribe to $CRBP
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

    IPO Year:

    Exchange: NASDAQ

    Website: corbuspharma.com

    Peers

    $NBRV

    Recent Analyst Ratings for Corbus Pharmaceuticals Holdings Inc.

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform
    William Blair
    12/2/2024Overweight
    Piper Sandler
    7/30/2024$85.00Outperform
    Wedbush
    7/22/2024$80.00Buy
    H.C. Wainwright
    6/26/2024$85.00Buy
    B. Riley Securities
    6/3/2024$60.00 → $80.00Outperform
    Oppenheimer
    5/13/2024$77.00Outperform
    RBC Capital Mkts
    3/6/2024$4.00 → $46.00Hold → Buy
    Jefferies
    See more ratings

    Corbus Pharmaceuticals Holdings Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Corbus Pharmaceuticals Holdings Inc.

      10-Q - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/6/25 4:21:10 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      5/6/25 8:30:09 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.

      DEFA14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      4/1/25 4:36:19 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Corbus Pharmaceuticals Holdings Inc.

      DEF 14A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      4/1/25 4:35:05 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update

      8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      3/21/25 4:40:17 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      3/18/25 4:30:09 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Corbus Pharmaceuticals Holdings Inc.

      10-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      3/11/25 5:24:09 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Filer)

      3/11/25 8:30:07 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SCHEDULE 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      2/14/25 4:30:03 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Corbus Pharmaceuticals Holdings Inc.

      144 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      2/14/25 4:18:15 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Corbus Pharmaceuticals Holdings Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 7:48:14 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 6:41:20 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 4:05:29 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 4:00:05 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/14/24 3:09:02 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/12/24 2:34:40 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/12/24 9:37:37 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      11/4/24 11:28:21 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      10/15/24 4:19:16 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Corbus Pharmaceuticals Holdings Inc.

      SC 13G - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

      10/11/24 4:02:13 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Corbus Pharmaceuticals Holdings Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

      Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2025 RBC Capital Markets Global Healthcare Conference, to be held May 20-21, 2025 in New York, NY. 2025 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: May 21, 2025Time: 8:30 a.m. ETWebcast: Click here About CorbusCorbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people def

      5/8/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumorsSAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1 inverse agonist CRB-913Dose escalation study on schedule for completion in Q4 2025 for the anti-αvβ8 integrin mAB-CRB-601 in solid tumors NORWOOD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended March 31, 2025. "During the first quarter of 2025, we continu

      5/6/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

      CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-range finding scheduled for completion H2 2026 NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the

      3/28/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

      CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic cervical cancerCRB 913 SAD/MAD obesity study expected to start in March 2025$149m of cash & investments as of December 31,2024 and cash runway expected through Q3 2027 NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2024. "During the fourth quarter and into 2025, we made si

      3/11/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

      NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in the following upcoming investor conferences. B. Riley Securities Precision Oncology & Radiopharma Investor ConferenceFormat: Panel and one-on-one investor meetingsPanel Title: Unlocking the Full Potential of Nectin-4 Targeting TherapiesDate: February 28, 2025Time: 8:00 a.m. ET TD Cowen 45th Annual Health Care ConferenceFormat: Presentation and one-on-one investor meetingsDate: March 4, 2025Time: 1:50 p.m. ETWebcast: Click here Wedbush Securities Cardiometabolic Co

      2/25/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

      Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study Low levels of peripheral neuropathy and skin toxicity observed in both studies Clinical responses seen in urothelial (mUC) and cervical cancer participants in both studies First time targeting of head and neck squamous cell carcinoma (HNSCC) with CRB-701 yields multiple responses Dose optimization is underway with dosing at 2.7 mg/kg and 3.6 mg/kg Q3W  NORWOOD, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), announced that data from it

      2/14/25 7:30:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

      NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe ("Western study") of CRB-701 (SYS6002) has been released. The corresponding up-to-date data will be presented as a poster during the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The data from 31 patients referred to in the abstract dates to September 2024; the upcoming poster presentation will include data on 38 patients as of December 2024. ASCO GU will be held in San Francisco, CA February 1

      2/11/25 7:30:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference

      NORWOOD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the Guggenheim SMID Cap Biotech Conference, to be held February 5-6, 2025 in New York, NY Dr. Cohen will participate in analyst led fireside discussion and will attend one-on-one investor meetings. Guggenheim Securities SMID Cap Biotech ConferenceFormat: Fireside Chat and one-on-one investor meetingsPresentation Date: February 5, 2025Presentation Time: 2:30 PMWebcast: Click here About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity comp

      1/28/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

      NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced data from its first-in-human dose escalation clinical study conducted in the United States and the United Kingdom ("Western study") of CRB-701 (SYS6002) will be presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), to be held in San Francisco, CA February 13–15, 2025. The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tutors (Perez, et al) and will be

      1/8/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the 43rd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2025 in San Francisco, CA. Dr. Cohen will be presenting and attending investor meetings. 43rd Annual J.P. Morgan Healthcare ConferenceFormat: Presentation and one-on-one investor meetingsPresentation Date: January 16, 2025Presentation Time 11:15 a.m. PST The J.P. Morgan Healthcare Conference is invitation only. Those interested in attending should contact their J.P. Morgan representat

      1/6/25 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Corbus Pharmaceuticals Holdings Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Hodgson Ian claimed ownership of 25,977 shares (SEC Form 3)

      3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/18/25 4:45:04 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Smethurst Dominic sold $43,330 worth of shares (6,393 units at $6.78), decreasing direct ownership by 8% to 70,807 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/7/25 4:30:08 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Moran Sean F. sold $24,446 worth of shares (2,792 units at $8.76), decreasing direct ownership by 4% to 73,313 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/18/25 5:40:54 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Cohen Yuval sold $62,465 worth of shares (7,134 units at $8.76), decreasing direct ownership by 5% to 138,187 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/18/25 5:40:26 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Smethurst Dominic was granted 27,200 shares, increasing direct ownership by 54% to 77,200 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/4/25 5:14:53 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Moran Sean F. was granted 27,500 shares, increasing direct ownership by 57% to 76,105 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/4/25 5:13:17 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Cohen Yuval was granted 68,100 shares, increasing direct ownership by 88% to 145,321 units (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/4/25 5:11:39 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      9/24/24 4:04:18 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kung Winston was granted 5,566 shares (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      8/20/24 4:48:47 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Kung Winston

      3 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      8/20/24 4:45:11 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Corbus Pharmaceuticals Holdings Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cormorant Asset Management, Lp bought $7,003,761 worth of shares (350,000 units at $20.01) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      9/24/24 4:04:18 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $23,327,560 worth of shares (550,000 units at $42.41) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      3/11/24 5:34:06 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $14,250,000 worth of shares (750,000 units at $19.00) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      2/6/24 4:00:46 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormorant Asset Management, Lp bought $9,111,941 worth of shares (282,632 units at $32.24) (SEC Form 4)

      4 - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Issuer)

      1/30/24 4:23:10 PM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Corbus Pharmaceuticals Holdings Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Corbus Pharma

      William Blair initiated coverage of Corbus Pharma with a rating of Outperform

      2/28/25 7:22:12 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Corbus Pharma

      Piper Sandler initiated coverage of Corbus Pharma with a rating of Overweight

      12/2/24 9:55:40 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Corbus Pharma with a new price target

      Wedbush initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $85.00

      7/30/24 6:19:42 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright resumed coverage on Corbus Pharma with a new price target

      H.C. Wainwright resumed coverage of Corbus Pharma with a rating of Buy and set a new price target of $80.00

      7/22/24 7:19:58 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Corbus Pharma with a new price target

      B. Riley Securities initiated coverage of Corbus Pharma with a rating of Buy and set a new price target of $85.00

      6/26/24 7:30:17 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on Corbus Pharma with a new price target

      Oppenheimer reiterated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $80.00 from $60.00 previously

      6/3/24 7:44:57 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Corbus Pharma with a new price target

      RBC Capital Mkts initiated coverage of Corbus Pharma with a rating of Outperform and set a new price target of $77.00

      5/13/24 7:16:31 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharma upgraded by Jefferies with a new price target

      Jefferies upgraded Corbus Pharma from Hold to Buy and set a new price target of $46.00 from $4.00 previously

      3/6/24 8:09:25 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Corbus Pharmaceuticals

      Oppenheimer resumed coverage of Corbus Pharmaceuticals with a rating of Hold

      3/16/21 7:41:07 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Corbus Pharmaceuticals Holdings Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

      NORWOOD, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), today announced the appointment of Winston Kung to its Board of Directors. The appointment was effective as of August 16, 2024. Mr. Kung will also chair the Audit Committee. "With this track record of success in both the pharma industry and on Wall Street, Winston has earned a well-deserved reputation for his leadership and financial acumen," said Alan F. Holmer, Chairman of the Corbus Board of Directors. "We are delighted to welcome someone of Winston's stature and expertise to our Board and we look forward to his insights and guidance." "Winston brings an e

      8/20/24 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

      NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company's Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company's investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGFβ blocking monoclonal antibody targeting the integrin αvβ8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company's h

      2/28/24 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

      NORWOOD, Mass., March 6, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment of Yong Ben, M.D., MBA, to the Company's Board of Directors. "Dr. Ben is a distinguished oncology researcher and pharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition to our Board," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Our recent license agreement for CRB-701 has helped cement our position as a precision o

      3/6/23 8:00:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors

      NORWOOD, Mass., Sept. 26, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), an immunology company, today announced the appointment of Anne Altmeyer, PhD, MBA, MPH to its board of directors.   "Anne is a dynamic leader with a proven track record of advancing R&D programs and creating corporate value through successful business development transactions," said Alan Holmer, Chairman of the Board of Directors of Corbus. "Her corporate development expertise and oncology R&D experience will be invaluable to Corbus as we advance and

      9/26/22 8:05:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

      NEW YORK and LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LBT4) systems are implicated, today announced the appointment of Rachelle Jacques as President and Chief Executive Officer of Akari Therapeutics. Ms. Jacques will also join the company's Board of Directors. Her appointment begins at the end of March 2022. Outgoing Chief Executive Officer, Clive Richardson, will continue to serve the Company, supporting Rachelle to accelerate business development and ensuring a smooth transition."

      3/2/22 7:00:00 AM ET
      $AKTX
      $CRBP
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer

      NORWOOD, Mass., Dec. 7, 2021 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company") today announced the appointment of Rachael Brake, Ph.D., as Chief Scientific Officer, furthering the Company's mission of connecting innovation to purpose. Dr. Brake will build upon Corbus' commitment to immuno-oncology and joins the Company following the recent acquisition of monoclonal antibodies that inhibit TGFβ activation. Dr. Brake most recently served at Takeda Pharmaceuticals where she held multiple leadership roles across the R&D continuum, inc

      12/7/21 8:05:00 AM ET
      $CRBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors

      LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Rachelle Jacques to its Board of Directors. Ms. Jacques, who will serve on the Board's Audit Committee, has more than 25 years of industry experience in strategic, cross-functional executive roles spanning finance, business operations, manufacturing, and commercial. She has led successful launches of several rare disease therapies including the recent approval of a Regenerative Medicine Advanced Therapy (RMAT)-designated product, one of only three since the p

      10/21/21 9:30:00 AM ET
      $CRBP
      $QURE
      Biotechnology: Pharmaceutical Preparations
      Health Care